Voruciclib

Research use only, not for human use.

A potent, selective and orally bioavailable CDK9 inhibitor with Ki of 0.63 nM and 1.68 nM for CDK9/cyclinT2 and CDK9/cyclinT1, respectively.

A potent, selective and orally bioavailable CDK9 inhibitor with Ki of 0.63 nM and 1.68 nM for CDK9/cyclinT2 and CDK9/cyclinT1, respectively; also inhibits CDK6/cyclin D1, CDK4/cyclin D1, CDK1/cyclin B and CDK1/cyclin A with Ki of 3-10 nM, shows weak activity against MAK and ICK (Ki>250 nM); exhibits more selective target profile than flavopiridol, represses MCL-1 protein expression in preclinical models of DLBCL, causes tumor cell apoptosis and tumor growth inhibition combined with venetoclax in vivo.Blood Cancer Phase 1 Clinical

P 1446;P 1446A

Angiogenesis

CDK

CDK

Cancer

Blood cancer

1000023-04-0

469.84

C22H19ClF3NO5

>98% (HPLC)

——

O=C1C=C(C2=CC=C(C(F)(F)F)C=C2Cl)OC3=C([C@H]4[C@H](CO)N(C)CC4)C(O)=CC(O)=C13

2-[2-Chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidinyl]-4H-1-benzopyran-4-one

(-20℃)

With Ice Pack

≥ 2 years